Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
article

Has the threat of waiving COVID-19 vaccine intellectual property rights had its desired effect?

In this final article on the TRIPS waiver for COVID-19 vaccines, medicines, diagnostics and technologies, EPR’s Hannah Balfour considers whether it is the correct strategy to overcome COVID-19 treatment inequalities and explores other options.

In my earlier articles on the proposed Agreement of Trade-Related Intellectual Property Rights (TRIPS) waiver for COVID-19 vaccines, medicines, diagnostics and technologies, I explored the scope of the intellectual property (IP) rights waiver and its potential impacts on pharma, biopharma and biotech, should it be approved. In this last instalment, I focus on the supply of COVID-19 vaccines; discussing whether the IP waiver is the best solution for addressing COVID-19 vaccination disparities, what other strategies are helping to achieve this goal and whether the TRIPS waiver may already have achieved its desired effect.

DOWNLOAD SERIES EBOOK